AustralieFrV1, Main, Exploration, bibRecord, 004C19

The Impact of Lost Therapeutic Benefit (LTB) in High-Risk Hypertensive Patients: 2-Year Follow-Up Data from the Australian REACH Registry

Identifieur interne : 004C19 ( Main/Exploration ); précédent : 004C18; suivant : 004C20

The Impact of Lost Therapeutic Benefit (LTB) in High-Risk Hypertensive Patients: 2-Year Follow-Up Data from the Australian REACH Registry

Auteurs : Zanfina Ademi [Australie] ; Molla M. Huq [Australie] ; Danny Liew [Australie] ; Ph. Gabriel Steg [France] ; Deepak L. Bhatt [États-Unis] ; Mark Nelson [Australie] ; Christopher M. Reid [Australie]

Source :

Cardiovascular therapeutics : (Print) [ 1755-5914 ] ; 2013.

RBID : Pascal:14-0012317

Descripteurs français

Pascal (Inist)
- Traitement, Facteur risque, Hypertension artérielle, Homme, Thrombose, Hypertenseur, Athérosclérose.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Atherosclerosis, Human, Hypertension, Hypertensive drug, Risk factor, Thrombosis, Treatment.

Abstract

Objective: The aim of the study is to determine the extent of lost therapeutic benefit (LTB) in the hypertensive patients, and to determine the relationship between the presence of LTB and clinical outcomes. Methods: Prospective-cohort study of n = 2856 patients with or at high risk of atherothrombosis. LTB was calculated as the proportion of patients receiving blood pressure medication who were not attaining guideline blood pressure (BP) control targets (<140/90 mmHg). Logistic regression analysis was performed to identify predictors of LTB at baseline, and propensity score matching (PSM) was undertaken to estimate the treatment effects by matching case LTB and control non-LTB cohorts based on the nearest neighbor matching. Results: Of the total sample of 2856, 45.6% had uncontrolled BP, and LTB was present in 46.7% patients. The likelihood of LTB was less in males (OR = 0.78 [95% CI; 0.64-0.97]), and those with a previous myocardial infarction (OR = 0.66 [0.53- 0.81]) or heart failure (OR = 0.58 [0.42-0.82]). LTB was more common in those with diabetes (OR = 1.44 [1.16-1.79]), aged >65 years (OR = 1.36 [1.06-1.75]) and having an ABI < 0.09 in either leg at rest (OR = 1.30 [1.02-1.75]). Following PSM, the combination of ischemic events (55-64 age category) was more likely to occur in the LTB compared with non-LTB group (4.38% and 0.68%, respectively [P = 0.046]). Conclusion: Presence of HF, previous MI and being male decreased the likelihood of LTB, while presence of diabetes, age > 65 and ABI < 0.09 increased the risk of LTB. Patients with LTB in age category 55-64 had higher incidence of vascular events compared with those with non-LTB.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000625
to stream PascalFrancis, to step Curation: 005831
to stream PascalFrancis, to step Checkpoint: 000582
to stream Main, to step Merge: 004D56
to stream Main, to step Curation: 004C19

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The Impact of Lost Therapeutic Benefit (LTB) in High-Risk Hypertensive Patients: 2-Year Follow-Up Data from the Australian REACH Registry</title>
<author><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Medicine (The Royal Melbourne Hospital), Melbourne EpiCentre, University of Melbourne</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Melbourne, Vic.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Huq, Molla M" sort="Huq, Molla M" uniqKey="Huq M" first="Molla M." last="Huq">Molla M. Huq</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Melbourne, Vic.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Medicine (The Royal Melbourne Hospital), Melbourne EpiCentre, University of Melbourne</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Steg, Ph Gabriel" sort="Steg, Ph Gabriel" uniqKey="Steg P" first="Ph. Gabriel" last="Steg">Ph. Gabriel Steg</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-698, Université Paris 7 and AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Boston, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Menzies Research Institute Tasmania, School of Medicine, University of Tasmania</s1>
<s2>Hobart, Tas</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Hobart, Tas</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Melbourne, Vic.</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0012317</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 14-0012317 INIST</idno>
<idno type="RBID">Pascal:14-0012317</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000625</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005831</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000582</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000582</idno>
<idno type="wicri:doubleKey">1755-5914:2013:Ademi Z:the:impact:of</idno>
<idno type="wicri:Area/Main/Merge">004D56</idno>
<idno type="wicri:Area/Main/Curation">004C19</idno>
<idno type="wicri:Area/Main/Exploration">004C19</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The Impact of Lost Therapeutic Benefit (LTB) in High-Risk Hypertensive Patients: 2-Year Follow-Up Data from the Australian REACH Registry</title>
<author><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Medicine (The Royal Melbourne Hospital), Melbourne EpiCentre, University of Melbourne</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Melbourne, Vic.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Huq, Molla M" sort="Huq, Molla M" uniqKey="Huq M" first="Molla M." last="Huq">Molla M. Huq</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Melbourne, Vic.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Department of Medicine (The Royal Melbourne Hospital), Melbourne EpiCentre, University of Melbourne</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Steg, Ph Gabriel" sort="Steg, Ph Gabriel" uniqKey="Steg P" first="Ph. Gabriel" last="Steg">Ph. Gabriel Steg</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>INSERM U-698, Université Paris 7 and AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Boston, MA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Menzies Research Institute Tasmania, School of Medicine, University of Tasmania</s1>
<s2>Hobart, Tas</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Hobart, Tas</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Epidemiology & Preventive Medicine, Monash University</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Melbourne, Vic.</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cardiovascular therapeutics : (Print)</title>
<title level="j" type="abbreviated">Cardiovasc. ther. : (Print)</title>
<idno type="ISSN">1755-5914</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cardiovascular therapeutics : (Print)</title>
<title level="j" type="abbreviated">Cardiovasc. ther. : (Print)</title>
<idno type="ISSN">1755-5914</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atherosclerosis</term>
<term>Human</term>
<term>Hypertension</term>
<term>Hypertensive drug</term>
<term>Risk factor</term>
<term>Thrombosis</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Traitement</term>
<term>Facteur risque</term>
<term>Hypertension artérielle</term>
<term>Homme</term>
<term>Thrombose</term>
<term>Hypertenseur</term>
<term>Athérosclérose</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: The aim of the study is to determine the extent of lost therapeutic benefit (LTB) in the hypertensive patients, and to determine the relationship between the presence of LTB and clinical outcomes. Methods: Prospective-cohort study of n = 2856 patients with or at high risk of atherothrombosis. LTB was calculated as the proportion of patients receiving blood pressure medication who were not attaining guideline blood pressure (BP) control targets (<140/90 mmHg). Logistic regression analysis was performed to identify predictors of LTB at baseline, and propensity score matching (PSM) was undertaken to estimate the treatment effects by matching case LTB and control non-LTB cohorts based on the nearest neighbor matching. Results: Of the total sample of 2856, 45.6% had uncontrolled BP, and LTB was present in 46.7% patients. The likelihood of LTB was less in males (OR = 0.78 [95% CI; 0.64-0.97]), and those with a previous myocardial infarction (OR = 0.66 [0.53- 0.81]) or heart failure (OR = 0.58 [0.42-0.82]). LTB was more common in those with diabetes (OR = 1.44 [1.16-1.79]), aged >65 years (OR = 1.36 [1.06-1.75]) and having an ABI < 0.09 in either leg at rest (OR = 1.30 [1.02-1.75]). Following PSM, the combination of ischemic events (55-64 age category) was more likely to occur in the LTB compared with non-LTB group (4.38% and 0.68%, respectively [P = 0.046]). Conclusion: Presence of HF, previous MI and being male decreased the likelihood of LTB, while presence of diabetes, age > 65 and ABI < 0.09 increased the risk of LTB. Patients with LTB in age category 55-64 had higher incidence of vascular events compared with those with non-LTB.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Victoria (État)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Melbourne</li>
<li>Paris</li>
</settlement>
<orgName><li>Université de Melbourne</li>
</orgName>
</list>
<tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
</region>
<name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
<name sortKey="Huq, Molla M" sort="Huq, Molla M" uniqKey="Huq M" first="Molla M." last="Huq">Molla M. Huq</name>
<name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name>
<name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name>
<name sortKey="Reid, Christopher M" sort="Reid, Christopher M" uniqKey="Reid C" first="Christopher M." last="Reid">Christopher M. Reid</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Steg, Ph Gabriel" sort="Steg, Ph Gabriel" uniqKey="Steg P" first="Ph. Gabriel" last="Steg">Ph. Gabriel Steg</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C19 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004C19 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:14-0012317
   |texte=   The Impact of Lost Therapeutic Benefit (LTB) in High-Risk Hypertensive Patients: 2-Year Follow-Up Data from the Australian REACH Registry
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

The Impact of Lost Therapeutic Benefit (LTB) in High-Risk Hypertensive Patients: 2-Year Follow-Up Data from the Australian REACH Registry

The Impact of Lost Therapeutic Benefit (LTB) in High-Risk Hypertensive Patients: 2-Year Follow-Up Data from the Australian REACH Registry

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri